How Does the Gut Microbiome Affect Immunity?
July 17, 2026Core Framework & Diagram What Is Personalized Immunotherapy?
July 17, 2026
What Is Personalized Immunotherapy?
Same cancer, same drug — why did some people survive while others didn't?
By the Editors 1-min read
In 2013, President Obama's science advisors announced a major research initiative: Precision Medicine. The core idea: different people, even with the 'same disease,' have genetic, immune system, and lifestyle differences meaning they need different treatments.
This idea manifests most extremely in immunotherapy — because the immune system itself is one of each person's most unique 'personal signatures.' Two people's HLA genotypes, TCR libraries, NK cell activity, gut microbiome composition... almost impossible to be completely identical. Applying the same immunotherapy to two people with completely different immune 'fingerprints' — you simply shouldn't expect completely identical effects.
Personalized Immunotherapy transforms 'each person's immune system uniqueness' from ignored background noise into the core input of treatment design — using your immune fingerprint to design an exclusive treatment plan.
KEY TAKEAWAYS
01
Personalized immunotherapy's core logic: first precisely measure 'this patient's' immune fingerprint (HLA type, tumor mutation profile, TME typing, microbiome composition), then design or select exclusive plans based on these characteristics — rather than using uniform plans and gambling on probability.
02
mRNA individualized cancer vaccine (Moderna mRNA-4157) in KEYNOTE-942 Phase II trial reduced high-risk melanoma recurrence risk by approximately forty-four percent — the key milestone of individualized neoantigen vaccines going from concept to clinical evidence. The entire process: whole-exome sequencing → AI neoantigen selection → mRNA synthesis → vaccination, takes about six to eight weeks.
03
TIL therapy (Lifileucel) gained FDA approval in 2024 — extracting 'T cells that know the tumor best' from patient tumors, expanding in vitro, then reinfusing, is a milestone for individualized cell immunotherapy becoming a commercial product.
04
Gut microbiome is personalized immunotherapy's most unexpected and highest potential variable. 2018's three Science papers and 2022's FMT converting non-responders to responders research prove microbiome composition is an independent predictor of immunotherapy response — and can be intervened.
05
Personalized immunotherapy's logic isn't limited to cancer: autoimmune disease immune typing treatment, individualized vaccine strategies, precision immune aging management — all are extensions of the same 'first measure individual immune fingerprint, then customize intervention' logic.
Art 131
What Is Immunomics?
→
Art 132
What Is Single-Cell Immunology?
→
